Altaris Capital Partners

What Altaris Capital Partners does

Altaris Capital Partners is a healthcare-focused private equity investment firm founded in 2003 and headquartered in New York City. The firm exclusively acquires and builds companies across three healthcare subsectors: Medical Devices and Diagnostics, Pharmaceuticals and Life Sciences, and Tech-Enabled Services. Since inception, Altaris has invested in more than 50 companies and currently manages $9 billion-plus of equity capital across 11 active operating companies, generating returns through traditional private equity fund economics—management fees on committed capital and carried interest on realizations from institutional limited partners.

The firm's portfolio spans vertically integrated CDMOs and life sciences services (Minaris Advanced Therapies, Veranova, Forj Medical, Kindeva Drug Delivery, Padagis, Solesis), biosimulation and drug discovery software (Simulations Plus combined with Chemical Computing Group), healthcare technology services (Tegria, Sharecare), security imaging (Analogic, including its Leidos security JV), and specialty insurance assets (Trean). Notable platform combinations illustrate its consolidation playbook: Minaris Regenerative Medicine combined with Advanced Therapies to form a global pure-play cell and gene therapy CDMO with more than 730,000 square feet of infrastructure; Intricon and Minnetronix combined into Forj Medical, a six-facility vertically integrated medtech CDMO; and Simulations Plus announced for combination with Chemical Computing Group to create an AI-accelerated biosimulation drug-discovery platform.

Altaris pursues an active ownership model, operating as the investment manager of the Altaris Funds through its direct and indirect subsidiaries (Altaris, LLC is the legal entity, a New York-governed LLC). The firm supports portfolio companies with operating partners and senior healthcare executives (e.g., Operating Partner Ger Brophy, Ph.D.; Tegria CEO Craig Mengert), and selectively divests non-core or fully-realized assets (e.g., Clearwater sold to Sunstone Partners in October 2025). Geographic footprint spans the US (primary), UK, Germany, Japan, Indonesia, Singapore, and Costa Rica via portfolio operations.

Name

Altaris Capital Partners

Legal name

Altaris, LLC

Website

http://www.altariscap.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Altaris Capital Partners is a New York-based private equity firm founded in 2003 that exclusively acquires and builds healthcare companies across medical devices/diagnostics, pharmaceuticals/life sciences, and tech-enabled services, managing $9B+ of equity capital across 11 active operating companies.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity / Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare private equity
• Healthcare investment management
• Medical device manufacturing
• Pharmaceutical contract development
• Healthcare technology services

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales, Technology or R&D

Revenue model

1. Private Equity Management: Altaris generates returns through management of private investment funds focused on healthcare, collecting management fees and carried interest on portfolio company exits and realizations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Altaris is a healthcare-focused private equity firm that raises capital from institutional limited partners and invests in, acquires, and builds companies across three healthcare subsectors: Medical Devices and Diagnostics, Pharmaceuticals and Life Sciences, and Tech-Enabled Services. The firm manages $9+ billion in equity capital, has invested in 50+ companies since 2003, and currently operates 11 active portfolio companies, often consolidating complementary businesses into integrated platforms (e.g., Minaris Advanced Therapies, Forj Medical).

Differentiator

Problem solved

Functional benefit

Products and services

• Altaris Private Investment Funds
• Minaris Advanced Therapies
• Forj Medical

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Partnerships

Two partnerships are on record, tiered core.

• Chemical Computing GroupcoreStrategic or Co-development Partner · 16 June 2026Chemical Computing Group (CCG) is an existing Altaris portfolio company that will be combined with Simulations Plus upon closing. CCG provides molecular modeling and drug discovery software with its flagship Molecular Operating Environment (MOE) platform used across the global biopharma industry.
• LeidoscoreStrategic or Co-development Partner · 15 April 2026Leidos and Altaris formed a joint venture combining Leidos' Security Enterprise Solutions business with Altaris-owned Analogic to create a U.S.-based security screening company. Leidos contributes approximately 1,500 employees and $625 million in projected 2026 revenue. The combined entity operates under the Analogic brand with Leidos retaining significant minority ownership.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Welsh, Carson, Anderson & Stowe (WCAS): Healthcare-services-focused private equity firm that, like Altaris, has built a 30+ year track record of majority-buyout investments across healthcare sub-sectors (services, technology, medical products). Both firms operate specialized, sector-dedicated models with similar fund sizes and active platforms.
• Bain Capital Life Sciences: Dedicated life-sciences investment franchise of Bain Capital that invests in pharma, biotech, medical devices, and healthcare services — mirroring Altaris's vertical approach to healthcare with both growth and buyout vehicles at comparable check sizes.
• Avista Capital Partners: Healthcare-specialist private equity firm with a long-running focus on pharmaceuticals, medical devices, and healthcare services. Compares directly to Altaris in scale, healthcare-only strategy, and active buyout platform.
• New Mountain Capital: Healthcare-focused private equity firm that owns and builds healthcare services, pharma services, and healthcare technology platforms. Similar to Altaris's pattern of taking controlling stakes in vertically integrated healthcare assets.
• GTCR: Long-tenured PE firm with a deep healthcare franchise across services, devices, and pharma. Runs a sector-dedicated model with multiple healthcare strategies, directly comparable in AUM tier and operational involvement to Altaris.

Broad incumbents

• KKR Health Care Strategic Growth: Dedicated healthcare growth-equity strategy within KKR covering pharma services, devices, and digital health. While backed by a broader generalist PE platform, its healthcare-only mandate and growth-equity focus makes it a closely comparable specialist peer to Altaris.
• TPG (TPG Capital / TPG Healthcare): Global alternatives manager with dedicated healthcare buyout and growth vehicles. Comparable in deploying large healthcare-focused equity capital across services, devices, and pharma — broader firm scale than Altaris but a directly overlapping healthcare PE practice.
• The Carlyle Group (Carlyle Healthcare): Global alternatives platform with a multi-billion-dollar healthcare practice spanning pharma services, devices, and healthcare technology. Comparable to Altaris in deal volume and healthcare sub-sector breadth but operated within a much larger generalist firm.
• Blackstone Life Sciences: Dedicated life-sciences investment platform of Blackstone focused on drug development, biopharma, and pharma services. Overlaps meaningfully with Altaris on pharma/CDMO and life-sciences investing despite being part of a much larger alternatives manager.

Emerging players

• Audax Private Equity (Audax Group): Healthcare-active middle-market PE firm executing buy-and-build platforms in healthcare services and medical products. Comparable to Altaris's repeatable platform-combination playbook though at smaller equity check sizes.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/altaris-capital-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A22 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altaris Capital Partners